What Do You Fear Most About Pulmonary Fibrosis?

What Do You Fear Most About Pulmonary Fibrosis?

Meet Dyane. She shares what she fears most about her pulmonary fibrosis diagnosis and explains how this diagnosis has impacted her life. The thing she hates the most is not being able to be an active grandmother, with her eight grandchildren. Watch the video to hear her story.

IPF Patients Seen to Benefit from Pirfenidone Treatment

An analysis of pooled data from three Phase 3 clinical trials in idiopathic pulmonary fibrosis (IPF) patients shows that treatment with pirfenidone for one year significantly reduced disease progression. The study, titled “Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials,” was published in…

Idiopathic Pulmonary Fibrosis Comorbidities Discussed By Researchers

A team of researchers from the Department of Clinical and Experimental Medicine at the University of Catania, Italy recently reviewed the co-occurrence of additional diseases in Idiopathic Pulmonary Fibrosis and their current therapeutic strategies. The study, entitled “IPF, comorbidities and management implications,“ was published in the Sarcoidosis Vasculitis…

Biomarkers Seen in Patients’ Blood Show Potential IPF Disease

Findings by a team of researchers suggest that levels of circulating endothelial cells and fibrocytes may be used as predictive biomarkers in idiopathic pulmonary fibrosis (IPF). The team’s study, “Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments,” was published in…

Phase 2 Clinical Trial For IPF Patients With Chronic Cough

Afferent Pharmaceuticals, a biotechnology company dedicated to therapies for neurogenic disorders, recently announced the beginning of a Phase 2 clinical trial to assess its candidate product AF-219 for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Neurogenic disorders are conditions associated with the…